Conclusions
Ours is a large cohort of TMA following HSCT in children. The prevalence of TMA in our study is 0.8% with an increasing trend in recent years. The mortality in our pediatric TMA cohort is 30% which is in contrast to the higher mortality reported in previously published small case series. HHV6 emerged as not only a risk factor for TMA but also associated with increased mortality in these patients. Studies exploring the pathophysiology of TMA and its relationship to other complications of HSCT and to prove the effect of HHV6 on complement on a molecular level are needed to optimize the outcome.
References
1. Jodele S, Davies SM, Lane A, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood . 2014;124(4):645-653. doi:10.1182/blood-2014-03-564997
2. Schoettler M, Lehmann LE, Margossian S, et al. Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort. Blood Adv . 2020;4(11):2536-2547. doi:10.1182/bloodadvances.2019001242
3. Epperla N, Li A, Logan B, et al. Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. Br J Haematol . March 2020. doi:10.1111/bjh.16457
4. Davies JOJ, Hart AC, De La Fuente J, Bain BJ. Macrophage activation syndrome and post-transplant microangiopathy following haploidentical bone marrow transplantation for sickle cell anemia. Am J Hematol . 2018;93(4):588-589. doi:10.1002/ajh.24995
5. Matsuda Y, Hara J, Miyoshi H, et al. Thrombotic microangiopathy associated with reactivation of human herpesvirus-6 following high-dose chemotherapy with autologous bone marrow transplantation in young children. Bone Marrow Transplant . 1999;24(8):919-923. doi:10.1038/sj.bmt.1702003
6. Dvorak CC, Higham C, Shimano KA. Transplant-Associated Thrombotic Microangiopathy in Pediatric Hematopoietic Cell Transplant Recipients: A Practical Approach to Diagnosis and Management. Front Pediatr . 2019;7:133. doi:10.3389/fped.2019.00133
7. Ye Y, Zheng W, Wang J, et al. Risk and prognostic factors of transplantation-associated thrombotic microangiopathy in allogeneic haematopoietic stem cell transplantation: a nested case control study.Hematol Oncol . 2017;35(4):821-827. doi:10.1002/hon.2310
8. Sakellari I, Gavriilaki E, Boussiou Z, et al. Transplant-associated thrombotic microangiopathy: an unresolved complication of unrelated allogeneic transplant for hematologic diseases. Hematol Oncol . 2017;35(4):932-934. doi:10.1002/hon.2346
9. Changsirikulchai S, Myerson D, Guthrie KA, McDonald GB, Alpers CE, Hingorani SR. Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. Clin J Am Soc Nephrol . 2009;4(2):345-353. doi:10.2215/CJN.02070508
10. Stem Cell Trialists’ Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol . 2005;23(22):5074-5087. doi:10.1200/JCO.2005.09.020
11. Keesler DA, St Martin A, Bonfim C, Seber A, Zhang M-J, Eapen M. Bone Marrow versus Peripheral Blood from Unrelated Donors for Children and Adolescents with Acute Leukemia. Biol Blood Marrow Transplant . 2018;24(12):2487-2492. doi:10.1016/j.bbmt.2018.08.010
12. Gavriilaki E, Sakellari I, Anagnostopoulos A, Brodsky RA. Transplant-associated thrombotic microangiopathy: opening Pandora’s box.Bone Marrow Transplant . 2017;52(10):1355-1360. doi:10.1038/bmt.2017.39
13. Heybeli C, Sridharan M, Alkhateeb HB, et al. Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. Am J Hematol . July 2020. doi:10.1002/ajh.25922
14. Biedermann BC, Sahner S, Gregor M, et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet . 2002;359(9323):2078-2083. doi:10.1016/S0140-6736(02)08907-9
15. Luft T, Dietrich S, Falk C, et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood . 2011;118(6):1685-1692. doi:10.1182/blood-2011-02-334821
16. Garcia-Maldonado M, Kaufman CE, Comp PC. Decrease in endothelial cell-dependent protein C activation induced by thrombomodulin by treatment with cyclosporine. Transplantation . 1991;51(3):701-705. doi:10.1097/00007890-199103000-00030
17. Uderzo C, Bonanomi S, Busca A, et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation . 2006;82(5):638-644. doi:10.1097/01.tp.0000230373.82376.46
18. Hoorn CM, Wagner JG, Petry TW, Roth RA. Toxicity of mitomycin C toward cultured pulmonary artery endothelium. Toxicol Appl Pharmacol . 1995;130(1):87-94. doi:10.1006/taap.1995.1012
19. Kohn S, Fradis M, Podoshin L, Ben-David J, Zidan J, Robinson E. Endothelial injury of capillaries in the stria vascularis of guinea pigs treated with cisplatin and gentamicin. Ultrastruct Pathol . 1997;21(3):289-299. doi:10.3109/01913129709021925
20. Takatsuka H, Wakae T, Mori A, et al. Endothelial damage caused by cytomegalovirus and human herpesvirus-6. Bone Marrow Transplant . 2003;31(6):475-479. doi:10.1038/sj.bmt.1703879
21. Rizzo R, D’Accolti M, Bortolotti D, et al. Human Herpesvirus 6A and 6B inhibit in vitro angiogenesis by induction of Human Leukocyte Antigen G. Sci Rep . 2018;8(1):17683. doi:10.1038/s41598-018-36146-0
22. Arai Y, Yamashita K, Mizugishi K, et al. Serum neutrophil extracellular trap levels predict thrombotic microangiopathy after allogeneic stem cell transplantation. Biol Blood Marrow Transplant . 2013;19(12):1683-1689. doi:10.1016/j.bbmt.2013.09.005
23. Gloude NJ, Khandelwal P, Luebbering N, et al. Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD. Blood . 2017;130(10):1259-1266. doi:10.1182/blood-2017-05-782870
24. Phan TL, Carlin K, Ljungman P, et al. Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant . 2018;24(11):2324-2336. doi:10.1016/j.bbmt.2018.04.021
25. Santoro F, Kennedy PE, Locatelli G, Malnati MS, Berger EA, Lusso P. CD46 is a cellular receptor for human herpesvirus 6. Cell . 1999;99(7):817-827. doi:10.1016/S0092-8674(00)81678-5
26. Zipfel PF, Misselwitz J, Licht C, Skerka C. The role of defective complement control in hemolytic uremic syndrome. Semin Thromb Hemost . 2006;32(2):146-154. doi:10.1055/s-2006-939770
27. Grivel J-C, Santoro F, Chen S, et al. Pathogenic effects of human herpesvirus 6 in human lymphoid tissue ex vivo. J Virol . 2003;77(15):8280-8289. doi:10.1128/jvi.77.15.8280-8289.2003